http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 08:00:38 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html <p>SK bioscience has submitted a Clinical Trial Application (CTA) to South Africa's health regulator, SAHPRA, for a Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate, according to a press release from the South Korea-based company.</p> <p>RSM01 was licensed from the Gates Medical Research Institute (Gates MRI), a nonprofit affiliated with the Gates Foundation, in February 2026. Gates MRI conducted early-stage research and Phase 1a clinical trials of RSM01 in adults. The Phase 1b study will enroll approximately 80 infants aged 2 weeks to 8 months to evaluate the candidate's safety and pharmacokinetic profile.</p> <p>RSV is a http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html Fri, 14 Aug 2026 08:00:38 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html <p>SK bioscience has submitted a Clinical Trial Application (CTA) to South Africa's health regulator, SAHPRA, for a Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate, according to a press release from the South Korea-based company.</p> <p>RSM01 was licensed from the Gates Medical Research Institute (Gates MRI), a nonprofit affiliated with the Gates Foundation, in February 2026. Gates MRI conducted early-stage research and Phase 1a clinical trials of RSM01 in adults. The Phase 1b study will enroll approximately 80 infants aged 2 weeks to 8 months to evaluate the candidate's safety and pharmacokinetic profile.</p> <p>RSV is a http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html Fri, 14 Aug 2026 08:00:38 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html <p>SK bioscience has submitted a Clinical Trial Application (CTA) to South Africa's health regulator, SAHPRA, for a Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate, according to a press release from the South Korea-based company.</p> <p>RSM01 was licensed from the Gates Medical Research Institute (Gates MRI), a nonprofit affiliated with the Gates Foundation, in February 2026. Gates MRI conducted early-stage research and Phase 1a clinical trials of RSM01 in adults. The Phase 1b study will enroll approximately 80 infants aged 2 weeks to 8 months to evaluate the candidate's safety and pharmacokinetic profile.</p> <p>RSV is a http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html Fri, 14 Aug 2026 08:00:38 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html <p>SK bioscience has submitted a Clinical Trial Application (CTA) to South Africa's health regulator, SAHPRA, for a Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate, according to a press release from the South Korea-based company.</p> <p>RSM01 was licensed from the Gates Medical Research Institute (Gates MRI), a nonprofit affiliated with the Gates Foundation, in February 2026. Gates MRI conducted early-stage research and Phase 1a clinical trials of RSM01 in adults. The Phase 1b study will enroll approximately 80 infants aged 2 weeks to 8 months to evaluate the candidate's safety and pharmacokinetic profile.</p> <p>RSV is a http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html Fri, 14 Aug 2026 08:00:38 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html <p>SK bioscience has submitted a Clinical Trial Application (CTA) to South Africa's health regulator, SAHPRA, for a Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate, according to a press release from the South Korea-based company.</p> <p>RSM01 was licensed from the Gates Medical Research Institute (Gates MRI), a nonprofit affiliated with the Gates Foundation, in February 2026. Gates MRI conducted early-stage research and Phase 1a clinical trials of RSM01 in adults. The Phase 1b study will enroll approximately 80 infants aged 2 weeks to 8 months to evaluate the candidate's safety and pharmacokinetic profile.</p> <p>RSV is a http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html Fri, 14 Aug 2026 08:00:38 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html <p>SK bioscience has submitted a Clinical Trial Application (CTA) to South Africa's health regulator, SAHPRA, for a Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate, according to a press release from the South Korea-based company.</p> <p>RSM01 was licensed from the Gates Medical Research Institute (Gates MRI), a nonprofit affiliated with the Gates Foundation, in February 2026. Gates MRI conducted early-stage research and Phase 1a clinical trials of RSM01 in adults. The Phase 1b study will enroll approximately 80 infants aged 2 weeks to 8 months to evaluate the candidate's safety and pharmacokinetic profile.</p> <p>RSV is a http://www.streetinsider.com/FDA/SK+bioscience+files+RSV+antibody+trial+application+in+South+Africa/26924754.html Fri, 14 Aug 2026 08:00:38 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/Press+Releases/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html <div class="xn-content"> <ul type="disc"><li><b>Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months</b></li><li><b>Company expands its global portfolio beyond vaccines into antibody-based preventive technologies</b></li><li><b>Growing global R&amp;D network strengthens capabilities in next-generation infectious disease prevention</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the <span>South African Health Products Regulatory Authority</span> (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the <span>Gates Medical Research Institute</span> http://www.streetinsider.com/PRNewswire/SK+bioscience+Advances+Development+of+Next-Generation+Infectious+Disease+Prevention+Platform+with+Global+Phase+1b+CTA+Submission+for+RSV+Preventive+Antibody+Candidate/26924739.html Fri, 14 Aug 2026 08:00:00 -0400 302440 A.14320728 A.50213909 O.20250741 O.20357061 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html <div class="xn-content"> <ul type="disc"><li><b>SK bioscience was selected to lead the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>-funded ROTOR project, establishing a global collaboration framework.</b></li><li><b>SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making.</b></li><li><b>The project will support next-generation injectable rotavirus vaccine development and contribute to expanding vaccine access in LMICs.</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 2, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it will lead the Research Optimization &amp; Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical development decision-support platform initiative funded by the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>, http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html Thu, 02 Jul 2026 08:00:00 -0400 302440 A.14320728 A.17568957 A.26378697 A.50213909 A.60012003 O.00043238 O.04889877 O.20250741 O.20357061 O.59470868 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html <div class="xn-content"> <ul type="disc"><li><b>SK bioscience was selected to lead the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>-funded ROTOR project, establishing a global collaboration framework.</b></li><li><b>SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making.</b></li><li><b>The project will support next-generation injectable rotavirus vaccine development and contribute to expanding vaccine access in LMICs.</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 2, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it will lead the Research Optimization &amp; Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical development decision-support platform initiative funded by the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>, http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html Thu, 02 Jul 2026 08:00:00 -0400 302440 A.14320728 A.17568957 A.26378697 A.50213909 A.60012003 O.00043238 O.04889877 O.20250741 O.20357061 O.59470868 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html <div class="xn-content"> <ul type="disc"><li><b>SK bioscience was selected to lead the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>-funded ROTOR project, establishing a global collaboration framework.</b></li><li><b>SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making.</b></li><li><b>The project will support next-generation injectable rotavirus vaccine development and contribute to expanding vaccine access in LMICs.</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 2, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it will lead the Research Optimization &amp; Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical development decision-support platform initiative funded by the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>, http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html Thu, 02 Jul 2026 08:00:00 -0400 302440 A.14320728 A.17568957 A.26378697 A.50213909 A.60012003 O.00043238 O.04889877 O.20250741 O.20357061 O.59470868 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html <div class="xn-content"> <ul type="disc"><li><b>SK bioscience was selected to lead the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>-funded ROTOR project, establishing a global collaboration framework.</b></li><li><b>SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making.</b></li><li><b>The project will support next-generation injectable rotavirus vaccine development and contribute to expanding vaccine access in LMICs.</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 2, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it will lead the Research Optimization &amp; Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical development decision-support platform initiative funded by the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>, http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html Thu, 02 Jul 2026 08:00:00 -0400 302440 A.14320728 A.17568957 A.26378697 A.50213909 A.60012003 O.00043238 O.04889877 O.20250741 O.20357061 O.59470868 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html <div class="xn-content"> <ul type="disc"><li><b>SK bioscience was selected to lead the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>-funded ROTOR project, establishing a global collaboration framework.</b></li><li><b>SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making.</b></li><li><b>The project will support next-generation injectable rotavirus vaccine development and contribute to expanding vaccine access in LMICs.</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 2, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it will lead the Research Optimization &amp; Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical development decision-support platform initiative funded by the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>, http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html Thu, 02 Jul 2026 08:00:00 -0400 302440 A.14320728 A.17568957 A.26378697 A.50213909 A.60012003 O.00043238 O.04889877 O.20250741 O.20357061 O.59470868 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html <div class="xn-content"> <ul type="disc"><li><b>SK bioscience was selected to lead the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>-funded ROTOR project, establishing a global collaboration framework.</b></li><li><b>SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making.</b></li><li><b>The project will support next-generation injectable rotavirus vaccine development and contribute to expanding vaccine access in LMICs.</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 2, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it will lead the Research Optimization &amp; Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical development decision-support platform initiative funded by the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>, http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html Thu, 02 Jul 2026 08:00:00 -0400 302440 A.14320728 A.17568957 A.26378697 A.50213909 A.60012003 O.00043238 O.04889877 O.20250741 O.20357061 O.59470868 SKBS http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html <div class="xn-content"> <ul type="disc"><li><b>SK bioscience was selected to lead the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>-funded ROTOR project, establishing a global collaboration framework.</b></li><li><b>SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making.</b></li><li><b>The project will support next-generation injectable rotavirus vaccine development and contribute to expanding vaccine access in LMICs.</b></li></ul><p><span class="legendSpanClass">INCHEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 2, 2026</chron></span> /PRNewswire/ -- SK bioscience announced that it will lead the Research Optimization &amp; Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical development decision-support platform initiative funded by the <span value="ACORN:5021390999" idsrc="xmltag.org" >Gates Foundation</span>, http://www.streetinsider.com/Press+Releases/SK+bioscience+Launches+AI-Powered+Initiative+to+Reduce+Uncertainty+in+Vaccine-Development+Decisions/26724169.html Thu, 02 Jul 2026 08:00:00 -0400 302440 A.14320728 A.17568957 A.26378697 A.50213909 A.60012003 O.00043238 O.04889877 O.20250741 O.20357061 O.59470868 SKBS